NMN dosing recommendations have been shaped by a growing body of clinical trials. Unlike many supplements where dosing is based on tradition or extrapolation from animal data, NMN now has multiple human dose-response studies to guide decisions.
What the Clinical Trials Used
| Study | Daily Dose | Duration | Key Finding |
|---|---|---|---|
| Irie et al. 2020 | 100-500 mg (single dose) | Single day | Safe at all doses tested |
| Yoshino et al. 2021 | 250 mg | 10 weeks | Improved muscle insulin sensitivity |
| Liao et al. 2021 | 300, 600, 1,200 mg | 6 weeks | Dose-dependent aerobic improvement |
| Okabe et al. 2022 | 250 mg | 12 weeks | Significant NAD+ increase |
| Kim et al. 2022 | 250 mg | 12 weeks | Improved lower limb function |
| Pencina et al. 2022 | 1,000 mg (1x or 2x daily) | 14 days | Dose-related NAD+ increase |
| Yi et al. 2023 | 300, 600, 900 mg | 60 days | 600 mg optimal for NAD+ and performance |
| Pencina et al. 2023 | 1,000 mg 2x daily | 28 days | Reduced weight, BP, cholesterol |
Recommended Starting Dose: 250 mg/day
For adults beginning NMN supplementation, 250 mg/day is a reasonable starting point. This dose has been shown to significantly increase NAD+ levels over 12 weeks (Okabe et al., 2022) and to improve muscle insulin sensitivity in a 10-week trial (Yoshino et al., 2021). Starting at this dose allows you to assess tolerance before increasing.
Optimal Dose Based on Current Evidence: 600 mg/day
The most informative dosing study is the Yi et al. multicenter trial, which directly compared 300, 600, and 900 mg/day against placebo. Blood NAD+ concentrations and walking endurance reached their peak at 600 mg/day, with the 900 mg group showing no further meaningful improvement on these measures (Yi et al., 2023). This suggests a plateau effect somewhere between 600 and 900 mg for general NAD+ support.
For most adults, 500-600 mg/day represents the current sweet spot between efficacy and cost.
Higher Doses (900-1,200 mg/day)
The Liao et al. runner trial found that 1,200 mg/day produced greater aerobic improvements than 300 mg/day (Liao et al., 2021). The MIB-626 trials used 1,000 mg once or twice daily with no safety concerns (Pencina et al., 2022; Pencina et al., 2023). Higher doses may benefit individuals seeking specific athletic or metabolic outcomes, but the incremental advantage over 600 mg is unclear for the average user. The cost also roughly doubles.
When to Take NMN
Morning vs. Afternoon
NAD+ metabolism follows a circadian rhythm, with NAMPT expression peaking during the day. This has led to a general recommendation to take NMN in the morning. However, the Kim et al. trial, which directly compared morning vs. afternoon dosing, found that the afternoon group showed larger effect sizes for physical function improvements (d = 0.72 for sit-to-stand vs. smaller effects in the morning group) (Kim et al., 2022).
The practical recommendation: take NMN at whatever time lets you be consistent. Consistency matters more than circadian optimization at this stage of the evidence.
With or Without Food
The Irie et al. pharmacokinetic study administered NMN without food, and plasma metabolite levels rose within 30 minutes (Irie et al., 2020). Some users report better tolerance when taking NMN with a small meal to reduce potential GI discomfort. Neither approach has been shown to significantly affect NAD+ elevation.
Dosing by Population
General Adult Health (30-50 years)
250-500 mg/day. The age-related NAD+ decline is present but less pronounced in this range. Starting at 250 mg is reasonable. The primary goal is maintenance-level NAD+ support.
Older Adults (50+)
500-600 mg/day. NAD+ decline accelerates with age, and this is the population where clinical benefits (walking endurance, lower limb function) have been most clearly demonstrated. The 600 mg dose showed optimal results in the Yi et al. trial, which enrolled adults 40-65 (Yi et al., 2023).
Athletes and Active Adults
600-1,200 mg/day. The aerobic capacity study found dose-dependent benefits up to 1,200 mg in runners training 5-6 days/week (Liao et al., 2021). Higher training volumes may increase NAD+ turnover, supporting the rationale for higher doses.
Metabolically At-Risk Adults
250 mg/day. The Yoshino et al. insulin sensitivity study used this dose and found significant benefits in prediabetic women (Yoshino et al., 2021). Higher doses have not been tested specifically in this population.
How Long Before You See Results?
Blood NAD+ levels begin rising within days of starting NMN. The Yi et al. trial measured significant NAD+ increases at 30 days (Yi et al., 2023). Functional outcomes like improved walking endurance and insulin sensitivity were measured at 8-12 weeks in the relevant trials. Give NMN at least 8 weeks at a consistent dose before evaluating whether it is working for you.
Subjective reports of improved energy, sleep, or recovery typically appear within 2-4 weeks, though these have not been rigorously measured in most trials.
Do You Need to Cycle NMN?
No. All published NMN trials used continuous daily administration. There is no evidence of tolerance development, receptor downregulation, or any other reason to cycle NMN on and off. Take it daily and consistently.
Safety Ceiling
Doses up to 1,250 mg/day for 4 weeks and up to 900 mg/day for 60 days have been tested with good tolerability and no significant adverse events (Pencina et al., 2022; Yi et al., 2023). There is no established upper limit for NMN, but the longest human safety data extends to 12 weeks. Taking doses substantially above 1,200 mg/day exceeds what has been studied.
References
-
Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160. PMID: 31685720
-
Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596
-
Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021;18(1):54. PMID: 34238308
-
Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. PMID: 35479740
-
Kim M, Seol J, Sato T, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. Nutrients. 2022;14(4):755. PMID: 35215405
-
Pencina KM, Lavu S, Dos Santos M, et al. MIB-626 increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023;78(1):90-96. PMID: 35182418
-
Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. Geroscience. 2023;45(1):29-43. PMID: 36482258
-
Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PMID: 36740954